---
title: Reduce motor symptoms with fasudil
nct_id: NCT05931575
phase: PHASE2
status: RECRUITING
sponsor: Technical University of Munich
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT05931575"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05931575"
last_fetched: "2026-05-10T14:03:08.316Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce motor symptoms with fasudil

**Goal (in five words):** Reduce motor symptoms with fasudil

**Official Title:** Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease (ROCK-PD)

**Trial ID:** [NCT05931575](https://clinicaltrials.gov/study/NCT05931575)

## Key Facts

- **Phase:** PHASE2
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Technical University of Munich
- **Target Enrollment:** 75 participants
- **Start Date:** 2023-09-11
- **Completion Date:** 2026-09-30
- **Conditions:** Idiopathic Parkinson´s Disease
- **Interventions:** Fasudil hydrochloride, Placebo
- **Intervention Types:** DRUG

## Summary For Families

The goal is to test whether blocking ROCK enzymes with fasudil is safe and can reduce neuroinflammation and support dopamine neuron health, which could ease motor symptoms and slow damage in Parkinson's. Fasudil is a ROCK inhibitor that alters cell scaffolding and inflammatory signals to help neurons survive and maintain axons, it is given in addition to usual Parkinson's drugs and does not replace levodopa. The trial is looking for people aged 30 to 80 with probable idiopathic Parkinson's at Hoehn and Yahr stages 1 to 3, who are non‑fluctuating with no wearing-off or dyskinesia and have been on stable PD medication for at least 6 weeks. People with prior intracranial bleeding, uncontrolled blood pressure, serious liver or kidney problems, major psychiatric or cognitive disorders, or pregnancy are excluded.

## Eligibility

- **Minimum age:** 30 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1. Patients with a diagnosis of at least probable PD according to MDS criteria (Postuma et al. MovDis 2015) and
2. Hoehn \& Yahr stage 1 - 3
3. must be non-fluctuating (no wearing-off, no dyskinesia) and stable on symptomatic PD medication for at least 6 weeks
4. age: 30 - 80 years
5. Women of childbearing potential must be non-lactating and surgically sterile or using a highly effective method of birth control and have a negative pregnancy test. Acceptable methods of birth control with a low failure rate (i.e. less than 1% per year) when used consistently and correct are for example implants, injectables, combined oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence or vasectomized partner
6. Capable of thoroughly understanding all information given and giving full informed consent according to GCP

Exclusion Criteria:

1. Atypical, secondary Parkinsonian syndromes, PD mimics, or any other medical condition known to have an association with Parkinsonian syndromes, which might confound or obscure the diagnosis of PD
2. Patients with a history of intracranial bleeding, known intracerebral aneurysms or Moyamoya disease, or positive family history for the above. If only family history positive, MR- or x-ray-based cranial imaging not older than 24 months must confirm absence of bleeding, aneurysms, or Moyamoya
3. Presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment
4. Patients with known arterial hypotension (resting blood pressure \<90/60 mmHg) or previous hypotensive episodes or requiring treatment for increasing of blood pressure, such as fludrocortisone, midodrine, etilefrine, cafedrine, or theodrenaline
5. Patients with an uncontrollable or unstable arterial hypertensive disease (resting blood pressure \>180 mmHg systolic and/or \>120 mmHg diastolic under current antihypertensive medication)
6. Known pulmonary hypertension and any medication prescribed for treatment of pulmonary hypertension
7. Confirmed hepatic insufficiency or abnormal liver function (stable ASAT and/or ALAT greater than 3 times the upper limit of the normal range) and determined to be non-transient through repeat testing
8. Renal insufficiency with a glomerular filtration rate (GFR) \<60 ml/min/1,73m² (calculated by MDRD equation or byCKD-EPI equation) and determined to be non-transient through repeat testing
9. Major psychiatric disorder, significant cognitive impairment or clinically evident dementia precluding evaluation of symptoms
10. Hypersensitivity to any component of the IMP
11. Liable to be not cooperative or comply with the trial requirements (as assessed by the investigator), or unable to be reached in the case of emergency
12. Pregnant or breast-feeding females or females with childbearing potential, if no adequate contraceptive measures are used
13. Previous participation in another clinical study involving trial medication within the preceding 12 weeks or five terminal half times of the longest to be eliminated trial medications (whichever is longer) or previous participation in this trial
```

## Locations (1)

- Technische Universität München, Klinikum rechts der Isar, Klinik und Poliklinik für Neurologie, Munich, Germany _(48.1374, 11.5755)_
  - Paul Lingor, MD — (CONTACT) — paul.lingor@tum.de

## Central Contacts

- Paul Lingor, MD — (CONTACT) — +49 89 4140 8257 — paul.lingor@tum.de
- Andreas Wolff, MD — (CONTACT) — +49 89 4140 8237 — andreas.wolff@tum.de

---

*Canonical: https://parkinsonspathways.com/trial/NCT05931575*  
*HTML version: https://parkinsonspathways.com/trial/NCT05931575*  
*Source data: https://clinicaltrials.gov/study/NCT05931575*